SYRE Spyre Therapeutics, Inc. stock chart & analysis
Conviction 2HealthcareScan · Fri, Nov 6, 2026Spyre Therapeutics, Inc. (SYRE) closed at $103.86 (+7.53%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 65, RS Rating 99, -5.8% from its 52-week high, +216.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
SYRE technical analysis
Trend
SYRE is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 15.6% above the 50-day ($89.79) and 38.7% above the 200-day ($74.85). ADX(14) at 15 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 65, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.0× its 20-day average. It trades about $93.9M a day on average. ATR(14) is $5.02, 4.8% of price — its typical daily range. Chaikin Money Flow (0.18) shows accumulation.
Key levels
The chart pattern's support is $76.96 and its resistance $100.21. The 52-week range is $21.15 to $110.18; price is 5.8% below the high and 391.0% above the low. The VWAP anchored at the 52-week high is $90.00, below price.
Performance
SYRE returned +7.5% (1 week), +29.9% (1 month), -1.4% (3 months), +38.3% (6 months), +354.3% (1 year), +216.9% (year to date).
About Spyre Therapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Pharmaceutical Preparations · Listed 2016 · 112 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 14 – Aug 183 scans
- Breaking out nowAug 191 scan
- Setting upOct 261 scan
- Breaking out nowOct 271 scan
- Setting upNov 51 scan
Insider activity
SEC Form 4 transactions in SYRE · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Albers Jeffrey W. Director · Common Stock · 2026-08-07 | Exercise | 5K | $52K | 2026-08-07 | 2026-08-10 |
Albers Jeffrey W. Director · Common Stock · 2026-08-07 | Sell | 5K | $522K | 2026-08-07 | 2026-08-10 |
Albers Jeffrey W. Director · Common Stock · 2026-08-07 | Sell | 8K | $835K | 2026-08-07 | 2026-08-10 |
Albers Jeffrey W. Director · Common Stock · 2026-08-07 | Sell | 10K | $1.0M | 2026-08-07 | 2026-08-10 |
Albers Jeffrey W. Director · Stock Option (Right to Buy) · 2026-08-07 | Exercise | 5K | — | 2026-08-07 | 2026-08-10 |
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03 | Exercise | 7.5K | $109K | 2026-08-03 | 2026-08-05 |
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03 | Sell | 5.1K | $486K | 2026-08-03 | 2026-08-05 |
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03 | Sell | 2.3K | $221K | 2026-08-03 | 2026-08-05 |
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03 | Sell | 100 | $10K | 2026-08-03 | 2026-08-05 |
Burrows Scott L Chief Financial Officer · Stock Option (Right to Buy) · 2026-08-03 | Exercise | 7.5K | — | 2026-08-03 | 2026-08-05 |
SEC filings
EDGAR filings in SYRE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.